Bellecapital International Ltd. Increases Stake in Regeneron Pharmaceuticals, Inc.

Bellecapital International Ltd. has significantly increased its investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.1% during the fourth quarter, as outlined in its recent 13F filing with the Securities and Exchange Commission (SEC). After acquiring an additional 6,002 shares, Bellecapital now holds a total of 19,600 shares of the biopharmaceutical company. This investment represents roughly 2.5% of Bellecapital International Ltd.'s overall portfolio, positioning Regeneron as its 15th largest investment. The valuation of these holdings was approximately $13,962,000 based on the recent SEC filing.

Other Institutional Investments

In addition to Bellecapital's increase, numerous other significant investors have adjusted their positions in Regeneron Pharmaceuticals. Focus Financial Network Inc. boosted its holdings by 7.4% in the third quarter, bringing its total to 538 shares, valued at around $566,000. Americana Partners LLC made a new investment in Regeneron worth approximately $330,000, while Farther Finance Advisors LLC also increased its stake by 7.9%, acquiring an additional 53 shares to reach a total of 724 shares valued at about $761,000. Empire Life Investments Inc. invested approximately $5,030,000 to secure a new position in Regeneron. Finally, Van ECK Associates Corp. raised its holdings by 8.9% during the same quarter, owning 58,136 shares now valued at $61,115,000. It is notable that hedge funds and institutional investors currently hold about 83.31% of Regeneron’s stock.

Regeneron Pharmaceuticals Stock Information

As of the latest update, shares of Regeneron Pharmaceuticals opened at $698.74. The company showcases a healthy financial structure with a low debt-to-equity ratio of 0.09, a current ratio of 4.73, and a quick ratio of 3.95. With a market capitalization nearing $76.39 billion, its price-to-earnings (P/E) ratio stands at 18.25, alongside a P/E/G ratio of 2.34. Regeneron Pharmaceuticals has experienced a fluctuation in its stock prices, with a 12-month low of $642.00 and a high of $1,211.20. Current moving averages sit at $698.51 for the past fifty days and $868.16 for the last two hundred days.

Recent Earnings Reports

Regeneron Pharmaceuticals reported its earnings for the last quarter on February 4th, revealing an earnings per share (EPS) of $12.07, surpassing the analysts' consensus of $11.21 by $0.86. The company had a revenue of $3.79 billion for the quarter, beating expectations of $3.76 billion. The firm's return on equity was marked at 16.32%, with a robust net margin of 31.07%. Year-over-year, Regeneron saw a 10.3% increase in quarterly revenue. Analysts forecast that the company will post an EPS of 35.92 for the current fiscal year.

Dividends and Payout

Additionally, Regeneron Pharmaceuticals has announced a quarterly dividend to be paid on March 20th, with shareholders of record on February 20th receiving $0.88 per share. This amounts to an annualized dividend of $3.52, yielding approximately 0.50%. The company's payout ratio is relatively low at 2.30%, indicating a sustainable dividend policy.

Analyst Opinions

Recent analyst commentary on Regeneron has led to varied price targets. Bernstein Bank lowered its price target from $1,070.00 to $1,000.00, while TD Cowen also adjusted their target down from $1,230.00 to $1,030.00 but maintained a "buy" rating. Conversely, Leerink Partners raised its rating from "hold" to "strong-buy". Wolfe Research started coverage with an "outperform" rating and a target price of $1,150.00. Meanwhile, Oppenheimer reduced their target from $1,150.00 to $1,000.00, maintaining an "outperform" rating. Current data shows that the stock receives one sell rating, six hold ratings, seventeen buy ratings, and two strong buy ratings, averaging a consensus rating of "Moderate Buy" and a price target of approximately $973.13.

Company Overview

Regeneron Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of medications aimed at treating various medical conditions worldwide. Its notable products include EYLEA, which treats several eye diseases such as wet age-related macular degeneration and diabetic macular edema.

investment, stock, biopharmaceutical